|
Market Closed -
Nasdaq
04:00:00 05/09/2026 HKT
|
5-day change | 1st Jan Change | ||
| 59.01 USD | -0.20% |
|
+6.79% | +34.63% |
| 09-01 | Exelixis Wins Appeal in Patent Case Against MSN Laboratories | MT |
| 08-06 | Exelixis, Inc., Q2 2026 Earnings Call, Aug 05, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EXELIXIS, INC. | Bio Therapeutic Drugs | -0.20% | +6.79% | +34.63% | +59.66% | +198.48% | 14.65B |  | | |
- Stock Market
- Stocks
- EXEL Stock
- Charts Exelixis, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
